



Press Release

October 18, 2010

Astellas Pharma Inc.  
sanofi-aventis K.K.

## **Transfer of Manufacturing and Marketing Approval and Distribution Rights for the Anti-Allergic Drug “Intal<sup>®</sup>”**

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; Representative Director and President: Masafumi Nogimori) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the anti-allergic drug Intal<sup>®</sup> (sodium cromoglycate) to sanofi-aventis effective on January 1, 2011. This transfer of distribution rights is taking place based on the expiration of the contract.

The two companies also announced that the manufacturing and marketing approval for all Intal<sup>®</sup> products had been transferred from Astellas Pharma to sanofi-aventis as of October 1, 2010.

Intal<sup>®</sup> is the world’s first chemical mediator release inhibitor discovered by the British company Fisons (currently sanofi-aventis Group), and has seven different formulations. It is indicated for a wide range of allergic diseases, such as allergic conjunctivitis/vernal conjunctivitis, allergic rhinitis, atopic dermatitis caused by food allergies, and bronchial asthma.

The impact from this agreement on Astellas’ financial forecast on the current fiscal year (from April 1, 2010 to March 31, 2011) will be immaterial.

<Products for which sales rights will be transferred>

- ◆ Intal<sup>®</sup> Eyedrops 2%, Intal<sup>®</sup> Eye Drops UD2% (allergic conjunctivitis drug)
- ◆ Intal<sup>®</sup> Nasal Spray 2% (allergic rhinitis drug)
- ◆ Intal<sup>®</sup> Fine Granules 10% (food allergy drug)
- ◆ Intal<sup>®</sup> Capsule for Inhalation 20mg (asthma/allergic rhinitis drug)
- ◆ Intal<sup>®</sup> Aerosol 1mg, Intal<sup>®</sup> Nebulizer Solution 1% (asthma drug)

Contact : Astellas Pharma Inc.  
Corporate Communications  
TEL: 03-3244-3201

sanofi-aventis K.K.  
Communications  
TEL: 03-6301-4148